MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain

NCT ID: NCT02701075

Last Updated: 2017-02-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FDA-approved MC5-A Scrambler Therapy (MC5-A ST) is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a message of normality (sans pain) to the central nervous system. While preliminary research has demonstrated its efficacy in treating chronic neuropathic pain secondary to cancer and failed back surgery syndrome, its effectiveness in treating chronic neuropathic pain secondary to traumatic musculoskeletal injuries like those experienced in combat has not been investigated. The purpose of this prospective, double-blind, randomized controlled, study is to determine if the MC5-A ST is efficacious in altering the biological, psychological, and social components of the chronic neuropathic pain experience in military Service Members (SMs) with traumatic musculoskeletal extremity injuries.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Neuropathy Low Back Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MC5-A Scrambler Therapy

MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.

Group Type EXPERIMENTAL

MC5-A Scrambler Therapy

Intervention Type DEVICE

up to 10 sessions, each session lasting 30 minutes

MC5-A Scrambler Therapy Sham Device

The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.

Group Type SHAM_COMPARATOR

MC5-A Scrambler Therapy Sham Device

Intervention Type DEVICE

up to 10 sessions, each session lasting 30 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MC5-A Scrambler Therapy

up to 10 sessions, each session lasting 30 minutes

Intervention Type DEVICE

MC5-A Scrambler Therapy Sham Device

up to 10 sessions, each session lasting 30 minutes

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Calmare Calmare Sham

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* military service members (active duty \& retirees) between the ages of 18 and 79, inclusive
* neuropathic pain symptoms present for 3 months or greater prior to entry into the study
* rated pain intensity equal to or greater than 3 on NRS-11 pain scale
* painful peripheral neuropathy in an extremity that is the result of a traumatic injury (post-traumatic/ post-surgical neuropathy, stump pain, entrapment neuropathy), or low back pain with radiculopathy
* stable pain medication treatment regimen
* able to speak and read English, understand the study procedures, and consent to study participation

Exclusion Criteria

* pacemaker or other implantable devices
* vena cava, aneurysm clips, coronary or other vascular stents
* pregnancy via a pregnancy test
* history of epilepsy, brain injury, symptomatic brain metastases
* prior celiac plexus block, or other neurolytic pain control treatment, within 4 weeks
* wounds or skin irritation in areas where the electrodes are required to be placed
* cardiac ischemia within the previous 6 months
* severe arrhythmia
* documented history of moderate or severe traumatic brain injury
* latex allergies
* open wound over site of chronic pain
* unable to stop anti-epileptic medications or gabapentin over 2 weeks of MC5-A ST treatment
* history of electroanalgesia treatment (electroacupuncture, biomodulator, TENS) over last 30 days
* participation in the study would delay the medical board (MEB) processing of the service member off of active duty status or would delay a return to duty status to their home unit.
* metal implants such as cardiac pacemakers, automatic defibrillators, aneurysm clips, vena cava clips and skull plates
Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brooke Army Medical Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ann Marie Nayback-Beebe, PhD, RN

LTC Ann Marie Nayback-Beebe

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ann Marie Nayback-Beebe, PhD, FNP-BC

Role: PRINCIPAL_INVESTIGATOR

Brooke Army Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brooke Army Medical Center

Fort Sam Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TSNRP-N13-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Scrambler Trial for Pain in NMOSD
NCT03452176 COMPLETED NA
Selective Nerve Stimulation (SNS) Pilot Study
NCT01259271 COMPLETED EARLY_PHASE1